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Abstract: We report a case of a patient with age-related macular degeneration, who had 
undergone trabeculectomy nine years earlier, and developed severe hypotony and bleb leak 
after treatment with intravitreal injections of ranibizumab. Although the incident is rare, in 
patients with longstanding ﬁ  ltering blebs, who need treatment with antivascular endothelial 
growth factors, close follow-up may be advocated, since the occurrence of bleb rupture could 
lead to permanent vision loss.
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Introduction
Trabeculectomy was introduced by Cairns in 1968 and until today is the most common 
surgical procedure for the treatment of glaucoma.1,2 The procedure is supposed to 
remove a portion of trabecular meshwork to allow ﬂ  ow into the cut ends of Schlemm’s 
canal, using a partial thickness scleral ﬂ  ap to cover the sclerostomy;1,2 and thus a ﬁ  stula 
is created between the anterior chamber and the subjuconjunctival space.
We report case of a patient with age-related macular degeneration (AMD) who 
had undergone trabeculectomy nine years earlier and developed severe hypotony and 
bleb leak after injection with antivascular endothelial growth factor (VEGF) which 
has never been reported before to the best of our knowledge.
Case presentation
A 71-year-old man was referred to us with the diagnosis of exudative maculopathy 
due to AMD in his right eye. He denied a history of systemic illness, eye injury, use 
of any medication, apart from diabetes mellitus. The patient was a nonsmoker.
Nine years ago, he had undergone uncomplicated trabeculectomy without any 
adjuncts for the treatment of primary open angle glaucoma. His intraocular pressure 
(IOP) had been within normal limits without any additional medication, post trabeculec-
tomy. Four years after trabeculectomy, he underwent uncomplicated phacoemulsiﬁ  cation 
and his visual acuity (VA) was recorded to be 20/30 a month after surgery.
On examination VA of the right eye was 20/800 and fundus examination revealed 
a macular elevation and submacular hemorrhage; Fluorescein angiography depicted 
a predominantly classic subfoveal choroidal neovascularization (CNV) in the right 
eye, and the patient was diagnosed as having exudative AMD. After a discussion 
about the risks and beneﬁ  ts of intravitreal anti-VEGF therapy, the patient consented 
to treatment and received two intravitreal injections of ranibizumab (Lucentis) with a 
one-month interval. After each intravitreal injection G. Tobramycin qid was prescribed, 
for three days.
Three weeks after the second injection of Lucentis, the patient presented with 
discomfort, tearing, and blurred vision. Visual acuity was “light perception”, IOP Therapeutics and Clinical Risk Management 2009:5 18
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was 2 mmHg, and cornea was edematous with descemet 
folds (Figure 1). Seidel test was positive, indicating leakage 
from the thinned bled.
The patient was taken to theatre where the above ﬁ  nd-
ings were conﬁ  rmed and a vitreous strand coming out of the 
ruptured bleb was noted. During surgery careful dissection 
of the vitreous from the surgical wound was performed 
(Figure 2) and the gap of tissue in sclerostomy site was 
covered with human pericardium; subsequently conjunctiva 
was sutured above it.
The next day after surgery, the anterior chamber was well 
formed, IOP was 10 mmHg and VA improved to “counting 
ﬁ  ngers”. Six weeks later, Seidel test was negative, the IOP 
was 12 mmHg and the retina attached.
Discussion
Age-related macular degeneration is the most common cause 
of visual loss in patients over 65 years of age.3,4 Neovascular 
AMD with the development of CNV in the macular area 
accounts for 80% of the severe loss of visual acuity due to 
AMD.3,4 Ranibizumab is a recombinant humanized immu-
noglobulin G1 and isotype monoclonal antibody fragment 
designed for intraocular use which binds to and inhibits the 
biologic activity of human vascular endothelial growth factor 
A. The latter is believed to contribute to the development 
and/or progression of choroidal neovascularization associ-
ated with neovascular (wet) AMD.5,6 Results of the MARINA 
study and many other reports support the favourable results 
of ranibizumab.6
Recently, another anti-VEGF, bevacizumab, has been 
used as an adjunct for reducing the incidence of bleb failure 
Figure 1 At presentation;  note the extremely thin and avascular bleb and the descemet 
folds in the cornea secondary to hypotony.
Figure 2 In theatre; note the vitreous strands coming out of the sclerostomy site.
after trabeculectomy7,8 and the six-month outcomes are 
encouraging.7
In our case, we postulate that the anti-VEGF intravitreal 
as an angiogenesis inhibitor, ranibizumab, prevented the 
formation of new blood vessels, resulting in a lack of supply 
of oxygen and nutrients to the tissues. This may have resulted 
in ischemia and necrosis (consequently inhibiting reversal 
of the process and impairing wound healing) which led to 
the bleb leak and the severe hypotony in our patient. The 
fact that our patient was diabetic should be also taken into 
consideration. Coote and colleagues reported that a single 
subconjunctival bevacizumab injection led to a dramatic 
reduction in bleb vascularity for six weeks.8 Similarly, in our 
patient, the reduction of the bleb vascularity may have led to 
gradual thinning and ﬁ  nally to bleb rupture.
It is highly unlikely that the latter is due to chance 
since the ﬁ  ltering surgery had been performed nine years 
previously. The bleb leak occurred three weeks after the 
second injection of Lucentis and this could be attributed 
to the fact that it takes time for an anti-VEGF to shut 
down the existing vessels that supply the bleb, leading to 
ischemia and necrosis.
On the other hand wound-healing problems have been 
reported after systemic use of bevacizumab,9 however, in 
surgical oncology there is little evidence to link anastomotic 
leak with bevacizumab use.10
In conclusion, although the incident is rare and data 
from one patient cannot establish a cause effect relation-
ship between treatment and side-effects, in patients with 
longstanding ﬁ  ltering blebs that need anti-VEGF treatment, 
a closer follow up of the patient could be considered, since 
the occurrence of bleb rupture could lead to permanent 
vision loss.Therapeutics and Clinical Risk Management 2009:5 19
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